Compare Lufax Holding Ltd (LU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs TG Therapeutics Inc — how do they compare? Lufax Holding Ltd trades at $1.52 (market cap $2.41B), while TG Therapeutics Inc trades at $49.66 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 3.2× Lufax Holding Ltd's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| LU | TGTX | |
|---|---|---|
Market Cap | $2.41B | $7.64B |
Sector | Technology | Health |
52-Week High | $4.40 | $59.06 |
52-Week Low | $1.23 | $26.94 |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lufax Holding Ltd (LU) trades at $1.53, down 7.83% over the past day, reflecting ongoing investor caution amid financial losses and legal challenges. The stock shows a bullish technical signal with moving averages supporting an uptrend, but fundamentals remain weak with a net loss of $2.1 billion in 2025 and negative profit margins. Recent news highlights board changes and a securities class action lawsuit, adding to uncertainty.
The outlook for LU is clouded by persistent unprofitability and legal risks, though low valuation ratios like P/S of 0.39 and P/B of 0.11 may attract value investors. Analysts are predominantly bullish with 69% buy ratings, but the stock faces significant headwinds from operational losses and regulatory scrutiny, requiring careful risk assessment for any investment.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
